Understanding Mechanisms of Acquired Resistance to BIBW2992.
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 10 Mar 2017 Status changed from active, no longer recruiting to completed.
- 14 Nov 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jan 2017.